United Therapeutics (UTHR) Operating Expenses (2009 - 2026)

United Therapeutics has disclosed Operating Expenses across 18 years of filings, most recently posting $455.7 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $455.7 million, up 10.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 9.03% YoY), and the FY2025 annual result was $1.7 billion, up 12.65% from the prior year.
• Operating Expenses came in at $455.7 million for Q1 2026 at United Therapeutics, up from $433.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $455.7 million in Q1 2026 to a low of $173.9 million in Q1 2022.
• The 5-year median for Operating Expenses is $354.6 million (2023), against an average of $338.0 million.
• Across the five-year window, Operating Expenses slumped 60.82% in 2022 and surged 44.45% in 2024, its largest moves.
• United Therapeutics' Operating Expenses stood at $315.9 million in 2022, then grew by 12.25% to $354.6 million in 2023, then rose by 6.66% to $378.2 million in 2024, then climbed by 14.62% to $433.5 million in 2025, then advanced by 5.12% to $455.7 million in 2026.
• The last three Operating Expenses figures came in at $455.7 million (Q1 2026), $433.5 million (Q4 2025), and $411.0 million (Q3 2025), per Business Quant data.